Geneesmiddelen | Horizonscan geneesmiddelen

Apixaban ^G Dabigatran ^G Dabigatran etexilate ^IND Ravulizumab ^IND Rivaroxaban ^IND

Emicizumab ^IND Eptacog beta (activated) Etranacogene dezaparvovec Fibrinogen Fidanacogene elaparvovec Valoctocogene roxaparvovec

Bempedoic acid Bempedoic acid / ezetimibe Evinacumab Inclisiran Volanesorsen

Allogenic immunomodulatory progenitor cells Angiotensin II Apabetalon

Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. ^IND Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) ^IND

Emiplacel

Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). ^IND Extension of indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance ^IND

Icosapent ethyl Regadenoson ^IND Tafamidis ^IND

Treprostinil Udenafil Valsartan / sacubitril ^IND Vericiguat

Avatrombopag

Crizanlizumab Daprodustat

Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ^BS

Ferumoxytol

Luspatercept Mepolizumab ^IND Pegcetacoplan Ravulizumab Romiplostim ^IND Roxadustat RP-L102 Thrombomodulin alfa Vadadustat Voxelotor

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.